Intra-cellular therapies reports fourth quarter and full-year 2020 financial results and provides corporate update

Successfully launched caplyta ® (lumateperone) in late march 2020 and demonstrated strong commercial execution in the midst of covid-19.

ITCI Ratings Summary

ITCI Quant Ranking